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The amygdala is fundamental for associative fear and extinction learning. Recently, also the central
nucleus of the amygdala (CEA) has emerged as a site of plasticity actively controlling efferent connections
to downstream effector brain areas. Although synaptic transmission is primarily mediated by glutamate
and GABA, neuropeptides critically inﬂuence the overall response. While neuropeptide Y (NPY) acting via
postsynaptic Y1 receptors exerts an important anxiolytic and fear-reducing action, the role of the pre-
dominantly presynaptic Y2 receptors is less deﬁned.
To investigate the role of Y2 receptors in the CEA we employed viral-vector mediated over-expression
of the Y2 selective agonist NPY3-36 in fear conditioning and extinction experiments. NPY3-36 over-
expression in the CEA resulted in reduced fear expression during fear acquisition and recall. Interest-
ingly, this effect was blocked by intraperitoneal injection of a brain-penetrant Y2 receptor antagonist.
Furthermore, over-expression of NPY3-36 in the CEA also reduced fear expression during fear extinction of
CS-induced but not context-related fear. Again, fear extinction appeared delayed by peripheral injection
of a Y2 receptor antagonist JNJ-31020028. Importantly, mice with over-expression of NPY3-36 in the CEA
also displayed reduced spontaneous recovery and reinstatement, suggesting that Y2 receptor activation
supports a permanent suppression of fear. Local deletion of Y2 receptors in the CEA, on the other hand,
increased the expression of CS-induced freezing during fear recall and fear extinction. Thus, NPY inhibits
fear learning and promotes cued extinction by reducing fear expression also via activation of presynaptic
Y2 receptors on CEA neurons.
© 2015 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
The amygdala controls emotional processing including fear and
anxiety (Pape and Pare, 2010; Sah et al., 2003). Fear, an emotional
arousal provoked by distinct learning processes is generally
investigated by Pavlovian fear conditioning, where an initially
neutral stimulus, such as a tone (conditioned stimulus, CS) is
repetitively paired with an aversive stimulus (unconditioned
stimulus, US). After a few pairings the CS elicits a fear reaction even
in the absence of a US (conditioned response, CR). Repetitivegy, Medical University Inns-
.
an).
Ltd. This is an open access article upresentation of the CS alone, however, triggers the formation of a
new memory, called extinction memory (LeDoux, 2000; Maren,
2005; Quirk and Mueller, 2008). In contrast to fear, extinction
memory is rather fragile, and consequently passage of time,
changing of context or re-experience of the initial traumatic event
may result in rapid recovery of the initial conditioned fear response
(Ji and Maren, 2007). The central nucleus of the amygdala (CEA), a
pivotal component for fear expression, also harbors a highly elab-
oratedmicro-network capable of diverse types of plasticity (Ciocchi
et al., 2010; Haubensak et al., 2010; Li et al., 2013; Wilensky et al.,
2006). CEA output is mediated by GABAergic neurons projecting
to different brain regions, including hypothalamus, brainstem and
bed nucleus of the stria terminalis (BNST) (Dong et al., 2001;
LeDoux et al., 1988). However, several neuropeptides signiﬁcantlynder the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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Recent evidence suggests that NPY, a 36-amino-acid peptide
known for its anxiolytic properties, is also involved in fear and
extinction learning (Broqua et al., 1995; Fendt et al., 2009; Gutman
et al., 2008; Lach and de Lima, 2013; Verma et al., 2012). NPY acts
through at least 5 different G protein-coupled receptors (Y1, Y2, Y4,
Y5 and y6) generally exerting a prolonged inhibitory action (Michel
et al., 1998).
Gutman et al. (2008) demonstrated that, NPY in the basolateral
amygdala reduces fear expression and facilitates extinction of a fear
potentiated startle response. However, NPY reduces fear expression
also in Y1KO mice, indicating that different NPY receptor subtypes
are contributing to the modulation of learned fear (Fendt et al.,
2009). Recently, we demonstrated that NPYKO mice displayed
faster acquisition, increased expression and impaired extinction of
conditioned fear. Interestingly, while Y1 and Y2 receptor single KO
mice exhibited only moderate changes in fear processing, the
phenotype of NPYKO mice was fully recapitulated in Y1Y2 receptor
double KO mice (Verma et al., 2012).
Therefore we propose that also Y2 receptors signiﬁcantly
modulate fear conditioning and extinction. To test this hypothesis
we combined viral vector mediated over-expression of the Y2
preferring agonist NPY3-36 and local deletion of Y2 receptors in
conditional knockout mice with fear conditioning and extinction
experiments. We demonstrate that NPY3-36 over-expression in the
CEA reduces the expression and facilitates the extinction of
conditioned fear, while local deletion of Y2 receptors from CEA
neurons results in the opposite effect.
2. Material and methods
2.1. Animals
All procedures involving animals and animal care were con-
ducted in accordance with international laws and policies (Direc-
tive 2010/63/EU of the European parliament and of the council of 22
September 2010 on the protection of animals used for scientiﬁc
purposes; Guide for the Care and Use of Laboratory Animals, U.S.
National Research Council, 2011) and were approved by the Aus-
trian Ministry of Science. All effort was taken to minimize the
number of animals used and their suffering.
Experiments were performed in adult male mice (10e16 weeks
old, weighing 25e30 g) maintained on a pure C57BL/6N back-
ground (Charles River, Sulzfeld, Germany). Conditional knockout
mice for the Y2 receptor (Y2lox/lox) as well as NPYKO mice were
backcrossed to a C57BL/6N background for at least 10 generations.
Mice were housed in groups of 3e5 animals under standard labo-
ratory conditions (12 h/12 h light/dark cycle, lights being on at
07:00, food and water ad libitum). Generation of NPYKO mice and
Y2lox/lox mice has been described in detail previously (Sainsbury
et al., 2002; Verma et al., 2012).
2.2. Production of viral vectors
For recombinant adeno-associated-virus (rAAV)-mediated
expression of Cre-recombinase-Green ﬂuorescent fusion
protein (Cre-GFP, or GFP alone as a control), rAAV serotype 2-based
vectors pseudotyped with rAAV serotype 2 capsid proteins (rAAV-
2/2) were prepared by a two-plasmid co-transfection procedure
using HEK293T cells (Grimm et al., 2003). The rAAV-Cre vector was
kindly supplied by Dr. Fred H. Gage, LaJolla, USA (Kaspar et al.,
2002). For production of rAAV-NPY3-36, a respective plasmid
(Genescript, USA) encoding the human prepro-NPY but lacking the
ﬁrst 2 amino acids of the resulting NPY was custom synthesized
and packaged into an rAAV backbone as described below (codonoptimized DNA sequence of NPY3-36: 50 GGTACCGCGGCCGCGC-
CACCATGCTGGGCAACAAGCGGCTGGGCCTGAGCGGCCTGACCCTGG-
CCCTGAGCCTGCTGGTCTGCCTGGGAGCACTGGCAGAGGCCAGCAAGC
CCGACAACCCCGGCGAGGACGCCCCTGCCGAGGACATGGCCCGGTACT
ACAGCGCCCTGCGGCACTACATCAACCTGATCACCCGGCAGAGATACG-
GCAAGCGGAGCAGCCCCGAGACACTGATCAGCGACCTGCTGATGCGG-
GAGAGCACCGAGAACGTGCCCCGGACCCGGCTGGAAGATCCCGCCATG
TGGTGATGAGTCGACGAGCTC-30). After processing in neurons, the
amino acid sequence of the resulting neuropeptide NPY3-36 is
identical to the corresponding mouse sequence.
The rAAV vector backbone was ﬂanked by rAAV serotype 2 ITRs
and encoded either Cre-GFP or GFP alone under the control of the
human cytomegalovirus early enhancer/promoter. rAAV vectors
expressing prepro-NPY3-36 were under the control of a truncated
version of the cytomegalovirus (CMV)-chicken b-actin (CBA) hybrid
promoter. This hybrid promoter contained the enhancer element
(585 to 287) of the CMV promoter fused upstream to the CBA
promoter with its ﬁrst exon and intron. For the truncated version,
754 bp of the intron were deleted keeping the 111 bp at the 50 and
51 bp at the 30 end of the intron. The helper plasmid pDP2rs
(Plasmid factory, Germany) carried the rAAV-2 rep gene and the
rAAV-2 cap gene together with essential adenoviral helper func-
tions. Harvest and puriﬁcation of rAAVs was performed by DOC-
lysis, iodixanol density gradient centrifugation and ion-exchange
chromatography, as previously described (Zolotukhin et al.,
2002). Puriﬁed vectors were stored in aliquots at 80 C. Physical
rAAV titers were determined by quantitative real-time PCR analysis
of the recombinant genome. Final titers were 6  1010 genomic
particles (GP)/ml and 3  1010 GP/ml for rAAV 2/2-GFP/Cre and
rAAV 2/2-GFP, respectively.
2.3. Stereotaxic microinjections of adeno-associated viral vectors
Adult (8e12 weeks of age), male Y2lox/lox mice from the same
litter were injected with either rAAV-Cre (6  107 GP/ml), or rAAV-
GFP (3  107 GP/ml) using a stereotaxic frame (Model 962, David
Kopf Instruments, California, USA) with blunt ear bars. Male C57BL/
6NCrl littermates (8e12 weeks) were used for rAAV-NPY3-36 in-
jections and rAAV-GFP in controls. Coordinates according to
Paxinos and Franklin (2001) were (in mm, from bregma): CEA:
A, 1.0; L, ±2.8; V, 4.9. Anesthesia was initiated by injection of
ketamine (160 mg/kg, i.p.; Gr€aub AG, Bern, Switzerland) and
maintained throughout the entire procedure by Sevoﬂurane (Sev-
orane, Abbott, Austria) inhalation (2e3%, mixed with oxygen/air).
Injection cannulas prepared from a stainless steel tube (guide
cannula gauge 23, injection cannula gauge 30, Coopers needle
works LTD., Birmingham, UK) were inserted bilaterally through
small holes drilled into the skull. The cannulas were connected by
polyethylene micro-tubes (0.28  0.61 mm, NeoLab, Heidelberg,
Germany) to 5 ml Hamilton syringes. 1 ml of rAAV vector was infused
on each side using micro-pumps (50 nl/min; Nexus3000, Chemyx,
Science-products, Germany). At the end of the infusion, cannulas
were kept in place for 5 min, and were then slowly withdrawn
within 2 min. After closing the wound, mice were single housed for
optimal recovery. Behavioral testing started 2 and 3 weeks after
injection enabling local over-expression of the Y2 receptor agonist
NPY3-36 (rAAV-NPY3-36) or local deletion of Y2 receptors (rAAV-
Cre), respectively.
2.4. Characterization of rAAV-NPY3-36
NPYKOmice were injected with 1 ml of rAAV-NPY3-36 vector into
the central amygdala as described above. The amygdala was
dissected after 3 weeks and peptides were extracted with 2 M
acetic acid. Homogenates were separated by HPLC and
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peptides as described in detail previously (Bellmann et al., 1991).
2.5. Chemicals
The Y2 receptor antagonist JNJ-31020028 was synthesized at
Janssen Research & Development LLC (San Diego, USA). JNJ-
31020028 injection solution was always prepared on the day of
the experiment by dissolving it in 20% of 2-hydroxypropyl-beta-
cyclodextrin in 0.9% NaCl (pH 7.4) and injected i.p. at a concentra-
tion of 20 mg/kg bodyweight.
2.6. Behavioral experiments
2.6.1. Fear conditioning paradigm
Fear conditioning was performed in context A consisting of a
transparent acrylic rodent conditioning chamber with a metal grid
ﬂoor that was enclosed by a sound attenuating chamber. Illumi-
nation was 80 lux and chambers were cleaned with 70% ethanol
after each session. Fear recall as well as fear extinction and
extinction recall were performed in a different context consisting of
a dimly illuminated (10 lux) chamber with black, smooth walls and
the ﬂoor cleaned with 1% acetic acid (context B).
2.6.1.1. Fear acquisition. On day 15 (context A) mice were subjected
to a differential fear conditioning paradigm in which one auditory
stimulus served as a CS (CSþ, 30 s white noise, 80 dB) because it
was explicitly paired with a US, whereas the second auditory
stimulus was not paired (CS, 30 s, 3.5 kHz, 80 dB). All animals
received 5 CS and 5 CSþ in an alternating order, starting with a
CSþ. The unconditioned stimulus co-terminating with each CSþ
consisted of a scrambled mild electric foot shock (0.5 mA, 2 s). A
short-term memory test was performed 2 h after acquisition to
divide both groups (rAAV-NPY3-36 and rAAV-GFP) into two equally
performing subgroups for cued fear testing and extinction. Thus,
50% of the rAAV-NPY3-36 and 50% of the rAAV-GFP injected mice
were injected i.p. with a brain-penetrating Y2 receptor antagonist
or vehicle before fear testing, respectively (for details see belowand
Results section).
2.6.1.2. Contextual fear testing and extinction. On day 16, all mice
were exposed to the conditioning context (context A) without
auditory stimulus presentation for 15 min to determine context
dependent freezing (ﬁrst 3 min) as well as context fear extinction
(time-course of freezing during 15 min analyzed in 1 min bins).
2.6.1.3. Cued fear testing and extinction. On day 17, CS-induced fear
recall and CS-induced extinction training was performed in context
B. After a 2 min habituation period, 5 CS (30 s, inter-stimulus
interval 5 s) were presented followed by 15 presentations of CSþ
(30 s, inter-stimulus interval 5 s). Two additional extinction ses-
sions (morning and evening, context B) were performed on day 18,
each consisting of 15 CSþ. Extinction recall was tested on day 19 by
presenting 5 CSþ in context B. Intraperitoneal (i.p.) injection of the
brain penetrant Y2 receptor antagonist JNJ-31020028 or vehicle
was performed 30 min before cued-fear recall followed by extinc-
tion training. Freezing to the 1st CS was taken as a measure for fear
recall/expression and the time-course of freezing to all 15 consec-
utive CS presentations as a measure for fear extinction.
2.6.1.4. Spontaneous recovery and reinstatement. To investigate the
stability and permanence of the extinction memory mice were
subjected to spontaneous recovery and reinstatement tests. Spon-
taneous recovery was tested 7 days after extinction recall (day 26)
by re-exposing the animals to 5 CSþ in the extinction context(context B). Reinstatement was performed 7 days later (day 33) by
exposing the mice to two un-signaled foot shocks (2 s, 0.5 mA,
inter-stimulus interval 60 s) in the conditioning context (context A)
and reinstatement testing was performed 24 h later (day 34) by
presenting 5 CSþ in context B (extinction context).
Behavior was recorded by a video camera and scored ofﬂine by a
pixel based analysis software (http://topowatch.sourceforge.net/,
TopoWatch v0.3). The parameters of the program (detection
threshold 246, freezing threshold 4) were validated previously
by comparison to the manual analysis of two experienced ob-
servers, as described in detail previously (Verma et al., 2012).
2.7. Histochemistry
2.7.1. Tissue preparation
After the ﬁnal behavioral experimentmicewere killed by carbon
dioxide gas inhalation or by injecting an overdose of thiopental
(Thiopental, Sandoz, Austria) for in situ hybridization and immu-
nohistochemistry, respectively. Brains were either snap frozen
(isopentane,70 C, 3 min) for in situ hybridization experiments or
perfused with 4% paraformaldehyde (PFA) for immunohistochem-
istry (Tasan et al., 2010).
2.7.2. In situ hybridization
In situ hybridization was performed as described previously in
detail (Hortnagl et al., 2013; Tasan et al., 2010). Oligonucleotides
used as probes were custom synthesized (Y2 mRNA, 50 GAC AGT
CAT TGC TCT GGA CCG CCA TCG TTG CAT TGT CTA CCA CCT GGA
GAG C 30 and 50 CGG AGG CTA CCA ATG TGT AAG GAC ACA GGT GTG
AAA GCA CAT GG 30; Cre-recombinase mRNA, 50 CCG TCT CTG GTG
TAG CTG ATG ATC CGA ATA ACT ACC TGT TTT GCC 30; Microsynth,
Balgach, Switzerland, puriﬁed by HPLC). Oligonucleotides
(2.5 pmol) were 30 end-labeled by incubation with [35S]a-dATP
(50 mCi; 1300 Ci/mmol, Hartmann Analytic GmbH, Braunschweig,
Germany) and terminal transferase (Roche Diagnostics, Basel,
Switzerland), as described previously in detail (Tasan et al., 2010,
2011). Hybridization was performed in 50% formamide, 4 SSC
(1 SSC is 150 mM NaCl, 15 mM sodium citrate, pH 7.2), 500 mg/ml
salmon sperm DNA, 250 mg/ml yeast tRNA, 1 Denhardt's solution
(0.02% Ficoll, 0.02% polyvinylpyrrolidone, and 0.02% bovine serum
albumin), 10% dextran sulfate, and 20 mM dithiothreitol (all from
Sigma) at 42 C for 18 h. The slides were washed at high stringency
conditions (50% formamide in 2 SSC, 42 C) and brieﬂy rinsed in
water followed by 70% ethanol, and dried. Slides were exposed to
BioMaxMR ﬁlms (Amersham Pharmacia Biotech, Buckinghamshire,
UK) together with [14C]-microscales for 7e14 days. For evaluation
of the hybridization signal at the cellular level, some slides were
dipped in Kodak NTB-2 photosensitive emulsion (Kodak, Rochester,
NY; diluted 1:1 with distilled water) at 42 C, air dried overnight,
and then exposed for 4e6 weeks at 4 C. The BioMax MR ﬁlms and
the dipped slides were developed with Kodak D19 developer.
Sections were counterstained with cresyl violet, dehydrated,
cleared in butyl acetate, and covered with a coverslip using Eukitt
(Merck, Darmstadt, Germany).
2.7.3. Immunohistochemistry
Immunohistochemical analysis was performed on free-ﬂoating,
PFA-ﬁxed, 40 mm thick coronal sections using indirect peroxidase
labeling, as described previously (Tasan et al., 2011). In brief, cor-
onal sections were incubated free ﬂoating in 10% normal horse or
goat serum (Biomedica, Vienna, Austria) in TriseHCl buffered saline
(TBS; 50 mM, pH 7.2) for 90 min, followed by incubation with
primary antiserum (rabbit anti-NPY 1:2000, Bellmann et al., 1991).
The resulting complex was visualized by incubation with horse-
radish peroxidase (HRP)-coupled secondary antibody (1:250
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immunoﬂuorescence sections were incubated in a tyramide signal
ampliﬁcation solution (1:100, TSA ﬂuorescein, in-house) for
3e8 min. Sections were mounted on slides and covered using
Vectashield mounting medium (Vector laboratories, Inc., Burlin-
game, USA).
2.8. Statistical analysis
Data are presented as means ± SEM. They were analyzed for
normal distribution and equal variances using GraphPad Prism
software (Prism 5 for Macintosh, GraphPad Software Inc., San
Diego, CA). Two-way ANOVA for repeated measurements with
Bonferroni post hoc test was used to analyze overall changes in
percentage freezing for time and treatment in acquisition and
extinction experiments. Statistical analysis of behavior comparing
two groups was done by Student's test or MannWhitney U test as a
non-parametric test. Analysis of multiple groups was done by one-
way ANOVA followed by Bonferroni post hoc test.
3. Results
3.1. Over-expression of NPY3-36 in the CEA
To investigate the role of exogenous Y2 receptor stimulation in
the central extended amygdala in fear conditioning we aimed for a
long-term activation of Y2 receptors within the central extended
amygdala, including the stria terminalis. Thus we performed local
injection of an rAAV-NPY3-36 vector resulting in over-expression of
the Y2 receptor speciﬁc ligand NPY3-36 in central amygdala neurons
of C57BL/6N mice (Fig. 1). rAAV-NPY3-36 encodes the respectiveFig. 1. Characterization and over-expression of viral vector derived NPY3-36 in the CEA. (A) C
vector derived NPY3-36 from an rAAV-Prepro-NPY3-36 injected NPYKO mouse (n ¼ 3) are fou
form, (C) schematic of rAAV vectors and illustration of the injection site in the CEA and (E) im
NPY3-36 injection into the CEA of a male C57Bl/6N mouse compared to (D) NPY IR of a rAAanalogue of prepro-NPY in the target neurons. Prepro-NPY3-36 is
processed to NPY3-36 and released by exocytosis (Noe et al., 2008).
The identity of NPY3-36 was conﬁrmed by subjecting amygdala
samples form rAAV-NPY3-36 and rAAV-GFP injected NPYKO mice to
HPLC and subsequent radio-immuno assay using synthetic NPYand
NPY3-36 as standards (Fig. 1A and B). Thus we achieved a perma-
nent, locally restricted over-expression of a Y2 receptor agonist in
the CEA (Fig. 1E) compared to endogenous NPY expression in an
rAAV-GFP injected control mouse (Fig. 1D).
3.2. Fear conditioning after NPY3-36 over-expression in the CEA
We next explored the role of NPYand Y2 receptors in associative
fear learning (Fig. 2A). Compared to rAAV-GFP injected controls
local over-expression of NPY3-36 in CEA neurons reduced acquisi-
tion (Fig. 2B, two-way ANOVA for repeated measurements: time:
F(4/84) ¼ 40.52, P < 0.0001, treatment: F(1/21) ¼ 4.55, P < 0.05 but no
interaction: F(4/84) ¼ 0.9, P > 0.05) and expression of conditioned
fear (Fig. 2C, E). While context freezing (pool of the ﬁrst 3 min for
fear expression, day 16) was similar in rAAV-NPY3-36 and rAAV-GFP
injected mice (Fig. 2D), freezing to the CS, when tested on day 17,
was reduced in mice over-expressing NPY3-36 in CEA neurons
(t(9) ¼ 2.25, P ¼ 0.05, Fig. 2E).
To investigate the speciﬁcity and selectivity of NPY3-36 over-
expression on fear recall we injected rAAV-NPY3-36 or rAAV-GFP
into the CEA and subsequently performed fear conditioning ex-
periments (Fig. 2A). Thirty minutes before cued fear recall half of
the animals were injected i.p. with a Y2 antagonist (JNJ-31020028,
20 mg/kg) and the other half with vehicle. Fear expression,
measured by % freezing to the ﬁrst CS, was analyzed in mice over-
expressing NPY3-36 in the CEA compared to rAAV-GFP injectedharacterization of NPY and NPY3-36 in HPLC and RIA, (B) the peptide NPY3-36 and viral-
nd in the same fraction after HPLC and RIA, suggesting correct processing to the active
munohistochemistry demonstrating site restricted over-expression of NPY after rAAV-
V-GFP injected control (Scale bar 200 mm).
Fig. 2. Local over-expression of the Y2 receptor agonist NPY3-36 in the CEA results in reduced acquisition and expression of fear. (A) Timeline of the experiment: C57BL/6N mice
were injected bilaterally with an rAAV-NPY3-36 vector or an rAAV-GFP vector in controls into the CEA (day 1) followed by fear conditioning and extinction experiments two weeks
later. Thirty min before fear testing half of the mice received an i.p. injection of the speciﬁc Y2 receptor antagonist JNJ31020028 while the other half was injected with vehicle (day
17), followed by additional extinction sessions under drug-free conditions (day 18), extinction recall (day 19) and spontaneous recovery and reinstatement procedures (day 26, 33,
and 34). The dashed square indicates the experiments depicted in Fig. 2. (B) Reduced acquisition and (C) reduced expression of CS induced freezing (2 h-short-termmemory) but (D)
no change during the ﬁrst 3 min of context freezing after NPY3-36 over-expression in the CEA. (E) Reduced long-term memory (day 17, freezing to the ﬁrst CS) in rAAV-NPY3-36
injected mice compared to rAAV-GFP injected controls and peripheral injection of a Y2 receptor antagonist blocks the reduced fear expression of rAAV-NPY3-36 injected mice. Data
are presented as means ± SEM, *P < 0.05 rAAV-GFP-vehicle compared to rAAV-NPY3-36-vehicle, #P < 0.05 rAAV-NPY3-36-vehicle compared to rAAV-NPY3-36-JNJ.
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CEA and pre-treated with a Y2 antagonist 30 min before testing
(day 17, Fig. 2E, two-way ANOVA: AAV injections: F(1/19) ¼ 6.25,
P < 0.05, i.p. injections: F(1/19) ¼ 3.45, P > 0.05 and interaction: F(1/
19) ¼ 3.03, P > 0.05). Bonferroni post hoc test revealed that mice
injected into the CEA with rAAV-NPY3-36 displayed signiﬁcantly
reduced freezing to the 1st CS when compared to rAAV-GFP
injected control mice, both treated with vehicle 30 min before
testing (t(3/19) ¼ 2.93, P < 0.05) while injections of the Y2 antag-
onist JNJ-31020028 before testing reversed the effects of NPY3-36
over-expression in the CEA (t(3/19) ¼ 2.61, P < 0.05). This suggests
that during fear recall the acute effects of Y2 stimulation by NPY3-
36 over-expression are blocked by systemic application of the Y2
receptor antagonist.
3.3. Fear extinction after NPY3-36 over-expression in the CEA
Mice with over-expression of NPY3-36 in the CEA and rAAV-GFP
injected controls were also subjected to extinction of context fear
and CS-induced fear on day 16 and 17, respectively (Fig. 3A). Both
groups displayed successful extinction of context fear, there was,
however, no effect of treatment (Fig. 3B, two-way ANOVA for
repeated measurements: time: F(14/308) ¼ 11.96, P < 0.0001, treat-
ment: F(1/22) ¼ 0.15, P > 0.05 and interaction: F(14/308) ¼ 1.23,
P > 0.05). According to the results of the STM test (Fig. 2C), both
rAAV-GFP and rAAV-NPY3-36 injected mice were divided into 2
equally performing groups for consecutive peripheral injection of
the brain-penetrant Y2 antagonist JNJ-31020028 or vehicle,
respectively. As shown in Fig. 3A, mice were injected i.p. with JNJ-
31020028 or vehicle 30 min before cued fear extinction (Fig. 3A).
Interestingly, while fear expression tested by comparing freezing to
the 1st CSþ was similar (Fig. 2E) cued fear extinction, measured by
comparing the freezing levels upon 15 consecutive CS, appeared
delayed in rAAV-GFP injected controls that were injected i.p. with
the Y2 antagonist JNJ-31020028, 30 min before the behavioral
experiment (Fig. 3C, two-way ANOVA for repeated measurements:time: F(14/140) ¼ 4.35, P < 0.0001, treatment: F(1/10) ¼ 8.31, P < 0.05
and interaction: F(14/140) ¼ 1.36, P > 0.05). Note also the increased
freezing to the CS in mice pre-treated with JNJ-31020028, sug-
gesting a generalization of fear (Fig. 3C, t(1/10) ¼ 2.28, P < 0.05).
Furthermore, a difference in freezing levels during cued fear
extinction was observed also in those mice that were injected with
rAAV-NPY3-36 into the CEA and treated with the Y2 antagonist
before extinction training (Fig. 3D, two-way ANOVA for repeated
measurements: time: F(14/140) ¼ 0.52, P > 0.05, treatment: F(1/
10) ¼ 11.29, P < 0.01 and interaction: F(14/140) ¼ 0.93, P > 0.05). On
the other hand, fear extinction appeared to be more prominent in
mice over-expressing NPY3-36 in the CEA (and i.p. vehicle)
compared to those with NPY3-36 over-expression in the CEA and
pretreatment with a peripheral injection of the Y2 antagonist. This
effect was probably depending on reduced fear expression. Thus,
we analyzed fear expression on extinction 2 (day 18, Fig. 3E) by
comparing the freezing level to the 1st CSþ (Fig. 3E, two-way
ANOVA: AAV injections: F(1/19) ¼ 2.16, P > 0.05, i.p. injections: F(1/
19) ¼ 16.56, P < 0.001 and interaction: F(1/19) ¼ 0.21, P > 0.05).
Bonferroni post-hoc test demonstrated that fear expression was
signiﬁcantly increased in rAAV-GFP (t(3/19) ¼ 2.61, P < 0.05) as well
as in rAAV-NPY3-36 (t(3/19) ¼ 3.13, P < 0.05) injected mice that had
been pre-treated with the Y2 antagonist before extinction 1 (day
17), indicating that in addition to altered fear expression also
extinction may have been affected. To demonstrate the speciﬁcity
of the Y2 antagonist, all groups were subjected to two additional
extinction trainings in a drug free state 24 and 48 h later (Fig. 4A).
Importantly, both groups that had been pre-treated with the Y2
antagonist during extinction 1 and consequently displayed higher
freezing levels, now successfully performed fear extinction,
demonstrating that the effect of Y2 receptor blockade was revers-
ible (two-way ANOVA for repeated measurements: time: F(2/
40) ¼ 15.03, P < 0.0001, treatment: F(3/20) ¼ 3.98, P < 0.05 and
interaction: F(6/40) ¼ 0.73, P > 0.05). Thus, during fear recall, all four
groups displayed equally low freezing levels, indicating successful
fear extinction (Fig. 4C).
Fig. 4. Local over-expression of the Y2 receptor agonist NPY3-36 in the CEA promotes long-term suppression of fear. (A) Timeline of the experiment: Following 2 additional sessions
of fear extinction under drug free conditions on day 18, mice were subjected to fear recall in context B on day 19, spontaneous recovery in context B on day 26, re-instatement in
context A on day 33 and re-instatement testing in context B on day 34 (dashed square indicates experiments depicted in Fig. 4). (B) All 4 groups of mice displayed equal freezing
levels during fear recall suggesting successful extinction learning. (C) Freezing levels during fear recall (same as last data points in (B) depicted again for better comparison to
spontaneous recovery and reinstatement data). Reduced freezing in mice over-expressing NPY3-36 in the CEA during spontaneous recovery while mice that were treated with a Y2
receptor antagonist during the 1st session of extinction (Fig. 3C and D) displayed increased freezing, (E) a tendency towards reduced freezing during reinstatement of NPY3-36 over-
expressing mice and signiﬁcantly increased freezing levels of mice that were treated with i.p. injections of a Y2 receptor antagonist during extinction training. Data are presented as
means ± SEM, #P < 0.05, ##P < 0.01 rAAV-NPY3-36-vehicle compared to rAAV-NPY3-36-JNJ and rAAV-GFP-vehicle compared to rAAV-GFP-JNJ.
Fig. 3. Local over-expression of a Y2 receptor agonist in the CEA reduced fear expression during extinction of CS-induced fear. (A) Timeline of the experiment: dashed square
indicates experiments depicted in Fig. 3. Mice with local-overexpression of NPY3-36 in the CEA were subjected to context extinction 24 h after fear acquisition (day16). Day 17: Mice
with local over-expression of NPY3-36 (or GFP in controls) in the CEA were injected i.p. with the Y2 receptor antagonist JNJ31020028 30 min before cued fear extinction. (B) There
was no difference in context extinction of rAAV-NPY3-36 injected mice compared to rAAV-GFP injected controls (same group as in Fig. 2D, however, analyzed was the whole time-
course for fear extinction). (C) Reduced fear expression during cued fear extinction after i.p. injection of a Y2 antagonist in rAAV-GFP injected controls and (D) peripheral injection of
a Y2 antagonist blocked the reduced fear expression of cued fear during extinction in those mice that were injected with an rAAV-NPY3-36 vector into the CEA (same groups as in
Fig. 2E analyzing, however, the time-course of freezing behavior during all consecutive CS presentations of the extinction session). (E) Increased fear expression during the 1st CS
presentation on extinction 2 (day18) under drug-free conditions of previously JNJ-31020028 treated mice. Data are presented as means ± SEM, *P < 0.05, **P < 0.01, #P < 0.05 rAAV-
NPY3-36-vehicle compared to rAAV-NPY3-36-JNJ and rAAV-GFP-vehicle compared to rAAV-GFP-JNJ.
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To investigate the stability of fear suppression after extinction
training, we explored two paradigms generally used to model
relapse of fear after successful extinction training: spontaneous
recovery and reinstatement (Fig. 4A). Interestingly, although both
groups, rAAV-GFP and rAAV-NPY3-36, treated with vehicle during
extinction day 1 did not display spontaneous recovery, those
treated with the Y2 antagonist displayed increased freezing (day
26, Fig. 4D, two-way ANOVA: AAV injections: F(1/19)¼ 2.30, P > 0.05,
i.p. injections: F(1/19) ¼ 21.15, P < 0.001 and interaction: F(1/
19) ¼ 1.06, P > 0.05). Bonferroni post-hoc test revealed that injection
of the Y2 receptor antagonist JNJ-31020028 facilitated the devel-
opment of spontaneous recovery in rAAV-GFP injected (t(3/
19) ¼ 2.58, P < 0.05) and rAAV-NPY3-36 injected mice (t(3/19) ¼ 3.90,
P < 0.01). Reinstatement tested 8 days after spontaneous recovery,
was evident in CEA-GFP mice, while there was a trend towards a
reduction in CEA-NPY3-36 mice (Fig. 4E, t(10) ¼ 2.71, P ¼ 0.061).
Interestingly, again both groups injected i.p. with the Y2 antagonist
before extinction session 1 showed increased freezing levels during
reinstatement testing (day 34, Fig. 4E, two-way ANOVA: AAV in-
jections: F(1/19) ¼ 7.01, P < 0.05, i.p. injections: F(1/19) ¼ 17.60,
P < 0.001 and interaction: F(1/19) ¼ 0.05, P > 0.05). Bonferroni post
hoc test revealed that pre-extinction i.p. injection of the brain-
penetrating Y2 antagonist JNJ-31020028 increased freezing dur-
ing re-instatement in rAAV-NPY3-36 (t(3/19) ¼ 3.12, P < 0.05) and
rAAV-GFP injected mice (t(3/19) ¼ 2.81, P < 0.05). These data indi-
cate, that Y2 receptor activation during fear extinction promotes
the long-term suppression of fear, while a Y2 receptor antagonistFig. 5. Local deletion of Y2 receptors in the CEA reduces the expression and impairs the ex
into the CEA, Y2lox/lox mice were subjected to a fear conditioning paradigm consisting of acqu
recall. (B) Bilateral targeting of the CEAwith an rAAV-Cre vector results in (C) strong expressi
and (E) absence of Y2 receptor mRNA locally restricted to the CEA compared to (D) an rA
section depicting the right amygdala. Behavioral testing revealed that local deletion of Y2 rec
cued fear. (H) Unchanged expression of context fear and context fear extinction, but (I) redu
the CEA compared to rAAV-GFP injected control mice (Scale bars in C 1 mm, D-E 500 mm).generates the opposite effect.3.5. Local deletion of Y2 receptors in the central amygdala
To investigate the role of endogenous NPYon Y2 receptors in the
CEA in fear conditioning and extinction we performed local, site-
restricted deletion of Y2 receptors. An rAAV-Cre vector was injec-
ted bilaterally into the CEA of conditional Y2lox/lox mice resulting in
local deletion of Y2 receptors from CEA neurons and fear condi-
tioning and extinction experiments were performed 3 weeks later
(Fig. 5A). Compared to rAAV-GFP injected controls there was a
marked reduction in Y2 mRNA (Fig. 5D and E) in the CEA.
While local deletion of Y2 receptors in the CEA did not alter the
acquisition of conditioned fear (Fig. 5F), freezing to the CS during
cued fear testing (day 23) was signiﬁcantly increased compared to
rAAV-GFP injected control mice (Fig. 5G, t(2) ¼ 2.75, P < 0.05).
Interestingly context dependent freezing, tested 24 h after fear
acquisition (day 22) was not changed (Fig. 5H). Extinction of
conditioned fear appeared delayed in mice with local deletion of Y2
receptors in CEA neurons, an effect that was presumably due to the
increased fear expression (Fig. 5I). This was mainly due to delayed
within session extinction or reduced fear expression, whereas
between-session extinction was similar as in rAAV-GFP injected
controls (two-way ANOVA for repeated measurements: time: F(3/
39) ¼ 8.81, P < 0.0001, treatment: F(1/13) ¼ 4.71, P < 0.05 and
interaction: F(3/39) ¼ 0.74, P > 0.05). These data indicate that
endogenous NPY acting on Y2 receptors in the CEA predominantly
reduces cued fear recall.tinction of conditioned fear. (A) Following the bilateral injection of an rAAV-Cre vector
isition, context and cued fear testing and 3 sessions of extinction followed by extinction
on of Cre recombinase mRNA in the CEA on an autoradiograph of a coronal brain section
AV-GFP injected control mouse on a representative autoradiograph of a coronal brain
eptors did not change (F) acquisition of conditioned fear but (G) increased expression of
ced fear expression during extinction of cued fear after local deletion of Y2 receptors in
Data are presented as means ± SEM, *P < 0.05.
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Our results identify NPYand presynaptic Y2 receptors in the CEA
as crucial components for the modulation of conditioned fear. We
demonstrate that chronic stimulation of Y2 receptors in the CEA
delays the acquisition and reduces the expression of fear. In
contrast, local deletion of Y2 receptors in CEA neurons increases the
expression of cued fear during recall.
As shown previously, Y2 receptors on CEA neurons are also
located on axon terminals in the BNST, hypothalamus and brain-
stem arising from CEA projection neurons (Tasan et al., 2010). This
suggests that in our experiments the rAAV-mediated over-expres-
sion of NPY3-36 reduced GABA release not only locally in the CEA,
but also from CEm projections and thus increased the activity of e.g.
BNST neurons. In particular the lateral part of the anterior BNST
that harbors predominantly GABAergic neurons (Poulin et al.,
2009) and receives dense projections from the CEA (Dong et al.,
2001) is involved in the mediation of anxiolytic-like behavior
(Gungor and Pare, 2014; Jennings et al., 2013; Sink et al., 2011). On
the other hand, GABAergic terminals in the CEAmay originate from
local interneurons, but also from projection neurons of BNST or
hypothalamus. Interestingly, we and others did not observe
immunohistochemical co-labeling of Y2 receptors and NPY in the
CEA (Stanic et al., 2006; Wood et al., 2015), suggesting that the
concept of Y2 receptors as auto-receptors (Broberger et al., 1997)
regulating and limiting NPY release does not hold true for the CEA
(Stanic et al., 2011). Thus, we rather propose Y2 receptors as hetero-
receptors that are expressed on afferent and efferent projections of
the CEm, while NPY is provided by multiple sources within this
system. Y2 containing projections are surrounded by NPY
expressing interneurons, providing a source of signiﬁcant, long-
term suppression of synaptic activity. During fearful stimuli
concomitant activation of these neurons with Y2 receptor-
containing ﬁbers may result in a time-lagged but prolonged ac-
tion of NPY limiting an otherwise excessive fear response (Heilig
et al., 1994; Heilig, 2004).
Recent evidence demonstrated a Y2 receptor dependent
reduction of mIPSC frequency in the BNST (Kash andWinder, 2006;
Pleil et al., 2012). Neuropeptides are released at relatively low
concentrations and during periods of high frequency ﬁring, but
display high receptor afﬁnity and prolonged duration of action. NPY
generally acts on different Y receptors (Y1, Y2, Y5) and is converted
to the Y2 receptor preferring agonist NPY3-36 by the action of
dipeptidylpeptidase IV (Mentlein et al., 1993; Pedrazzini et al.,
2003). Thus, NPY3-36 is a metabolite of endogenous NPY and may
diffuse within the central extended amygdala and along the stria
terminalis by volume transmission acting there on Y2 receptors
generating a prolonged inhibitory action by reducing the activity of
long-distance ﬁber tracts.
Compared to other amygdala nuclei, the highest levels of Y2
receptors are found in the CEA (Stanic et al., 2006; Tasan et al.,
2010; Wood et al., 2015). NPY that ultimately acts on these re-
ceptors may originate from multiple sources, such as local in-
terneurons but potentially also from afferent projections. Thus, we
aimed to recapitulate increased and prolonged expression of NPY
that speciﬁcally activates Y2 receptors by viral-vector-mediated
over-expression of the Y2 preferring agonist NPY3-36. This pre-
sumably resulted in increased NPY3-36 release not only locally in the
CEm but potentially also along the stria terminalis and at the
respective terminals, such as in the BNST or brain stem. The use of
AAV vectors to overexpress a Y2 receptor speciﬁc agonist or to
delete Y2 receptors in the CEA has several advantages but also
limitations. First, while permanent cannula implantation often re-
sults in inﬂammatory responses (Holguin et al., 2007) a one-time
injection of an rAAV vector is generally well tolerated (Tasanet al., 2010). Second, controlling the localization and the resulting
diffusion of an injected pharmacological compound in a small brain
area, such as the CEA is impossible. On the other hand, the use of
viral vectors allows a one-time injection and a precise post-hoc
visualization of the affected brain area including the identiﬁcation
of projection targets and a conﬁrmation of the expected neuro-
chemical results, such as local deletion of Y2 receptors in the CEA.
The viral vectors for NPY3-36 express the pre-pro-peptide allowing
its processing to the mature peptide within synaptic vesicles and
release from axon terminals even remote from the injection site.
However, a limitation of the viral vector approach is its permanent
over-expression and a reduced temporal resolution. Thus, it is
reasonable to assume that an altered fear acquisition in our ex-
periments had also an inﬂuence on the behavioral response during
fear recall and fear extinction. To reduce this potential pitfall we
combined AAV vector-mediated over-expression of NPY3-36 with
peripheral injection of a Y2 antagonist before fear recall and fear
extinction. Indeed, acute antagonism of Y2 receptors compensates
the reduced fear expression of CEA-NPY3-36 over-expressing mice
to the level of rAAV-GFP injected controls. This suggests that Y2
receptor stimulation in the CEA also affects fear expression during
fear recall and thus potentially also fear extinction. In particular, the
increased freezing of previously (extinction 1) JNJ-31020028
injected mice to the 1st CS on extinction 2 (day18, Fig. 3E) sug-
gests that also fear extinction may have been compromised by
peripheral injection of a brain-penetrant Y2 antagonist. Interest-
ingly, mice that were injected with the brain-penetrant Y2 receptor
antagonist JNJ-31020028 displayed increased freezing to the CS,
suggesting a generalization of fear, similar as previously reported
for Y2KO mice (Verma et al., 2012). On the other hand, since
increased freezing was only seen in response to auditory cues, but
not to the context, it may also represent a sensitization to auditory
stimuli, independent of fear conditioning. However, further studies
are needed to clearly distinguish Y2 receptor-mediated effects on
fear expression from those on fear extinction. Furthermore, the fact
that the systemic application of the Y2 receptor antagonist reduced
fear expression also in control mice suggests that Y2 receptors in
other brain areas, such as hypothalamus or hippocampus could also
contribute to fear extinction. Interestingly, mice over-expressing
NPY3-36 in CEm neurons and mice, which received rAAV-GFP in-
jections, both failed to exhibit spontaneous recovery or reinstate-
ment of fear. On the other hand, mice treated with a Y2 receptor
antagonist during extinction training displayed increased re-
emergence of conditioned fear. Because all mice received two
additional extinction trainings under drug-free conditions, the
presence of the Y2 receptor antagonist during extinction training 1
may have even consolidated fear memory. Long-term suppression
of fear is, however, important considering the labile and transient
nature of extinctionmemories obtained during exposure therapy in
humans contesting with strong and permanent fear memories (Ji
and Maren, 2007).
To investigate the role of endogenous NPY acting on Y2 re-
ceptors in the central extended amygdala we performed local
deletion of Y2 receptors in CEA neurons. These data suggest a Y2
receptor-dependent reduction of fear expressionwhile an apparent
delay of fear extinction may be due to the recued fear expression.
The difference between local over-expression of a Y2 receptor se-
lective ligand and local deletion of Y2 receptors could have several
reasons. Release of endogenous NPY is considerably lower than
over-expression of a Y2 speciﬁc agonist. Furthermore, local deletion
of Y2 receptors in CEm neurons will delete Y2 receptors from CEm
interneurons and from axon terminals in CEm projection areas,
such as the BNST, hypothalamus or brain stem (Tasan et al., 2010).
Local over-expression of a Y2 receptor preferring agonist will,
however, also target Y2 receptors located in other brain areas (e.g.
D. Verma et al. / Neuropharmacology 99 (2015) 665e674 673interneurons of the BNST, brain stem or projections to the CEm).
Thus, further experiments are needed to elucidate the role of Y2
receptors in CEm target areas (e.g. BNST, hypothalamus).
It is important to mention that NPY3-36 does not exclusively act
on Y2 receptors, but may have a similar efﬁcacy at Y5 receptors
(Durkin et al., 2000; Gerald et al., 1996). However, in the present
study we demonstrated that the behavioral effects of NPY3-36 over-
expression in the CEAwere fully reversed by peripheral injection of
the brain-penetrant Y2 receptor antagonist JNJ-31020028, sug-
gesting that Y2 receptors in the CEA are most relevant for pro-
cessing of fear.
Previous evidence suggests that Y2 receptor stimulation pro-
motes anxiety (Bacchi et al., 2006; Nakajima et al., 1998; Redrobe
et al., 2003; Tasan et al., 2010; Tschenett et al., 2003) but see also
(Kask et al., 1998). Here, we demonstrated that Y2 receptor acti-
vation reduces fear expression and facilitates fear extinction.
Different brain circuits are involved in fear and anxiety (Davis et al.,
2010;Walker et al., 2003;Walker and Davis, 1997) and Y2 receptors
may play different roles in the respective circuitries. However, a
similar effect is known for glucocorticoids and the alpha2-
adrenoreceptor antagonist yohimbine. Both provoke anxiety-like
symptoms but on the other hand are successfully used to pro-
mote fear extinction (Barrett and Gonzalez-Lima, 2004; Blundell
et al., 2011; Holmes and Quirk, 2010; Yang et al., 2006). In contrast,
benzodiazepines reduce anxiety-like behavior but inhibit fear
extinction (Graham et al., 2011; Milad and Quirk, 2012). Further-
more, the behavioral effects of our interventions, involving long-
term stimulation of Y2 receptors, may have triggered counter-
acting downstream adaptations. On the other hand, Fendt et al.
(Fendt et al., 2009) demonstrated recently that NPY produces a
signiﬁcant reduction in fear expression also in Y1KO mice, sug-
gesting that other Y receptors are equally involved. Y2 receptors
that are considerably expressed in limbic brain areas may represent
a reasonable candidate. This is in line with our recent ﬁnding in Y
receptor KO mice indicating a synergistic action of Y1 and Y2 re-
ceptors to reduce fear and promote extinction learning (Verma
et al., 2012). Fear reducing and possibly also extinction-
promoting effects of Y2 receptors may be mediated largely in the
central extended amygdala. It is well known that activation of CEA
neurons is necessary for fear conditioning (Nader et al., 2001). Thus,
inhibition of GABA-release from CEm projection neurons may be
accomplished by presynaptic Y2 receptors, disinhibiting down-
stream brain areas. At the same time, Y2 receptors on CEm affer-
ents, may promote fear extinction and a permanent suppression of
fear. Thus, we propose a concept, in which NPY in the CEA is a fear-
reducing neuromodulator that mediates its action in a timed
manner through multiple receptors by ﬁrst, acutely inhibiting
postsynaptic neurons predominantly via Y1 receptors and subse-
quently promoting a long-lasting inhibitory action on CEA projec-
tion neurons by presynaptic Y2 receptors.Conﬂict of interest
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